NCT05259319Active, not recruitingPhase 1
An open-label, multicentric, phase I study with expansion cohorts, evaluating the safety and the efficacy of combination of atezolizumab, tiragolumab and stereotactic body radiation therapy in patients with metastatic multiorgan cancer
Source: EU CTIS (euclinicaltrials.eu) · Last updated 16 Jul 2026
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 86 (estimated)
- First submitted
- 17 Sept 2024
- Start date
- 27 Nov 2024
- Lead sponsor
- Centr Georges Francois Leclerc
- NCT number
- NCT05259319
- EU CT number
- 2024-516717-20-00
- EudraCT number
- 2021-003848-25
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 86
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.
Sites (2)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centr Georges Francois Leclerc Coordinator of this site? Confirm its status | Dijon | France | Active, not recruiting |
| Centre Oscar Lambret Coordinator of this site? Confirm its status | Lille | France | Active, not recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.